This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
Carlo and Baker cover the latest developments with the Omicron variant, and break down what we know and what we still don't. Plus, a relatively tame Black Friday, and more.
Dr. Amesh Adalja, an infectious disease specialist and senior scholar at Johns Hopkins Center for Health Security, joined Cheddar to discuss the nations joining in on a travel ban against several African nations after South Africa reported the emergence of the omicron variant of COVID-19 currently worrying health experts. Adalja also added his own voice to the World Health Organization's objection to the travel ban at this time. "When you do a travel ban, you basically waste a lot of resources implementing the travel ban, you give people a false sense of security when the virus is likely already outside of the area of the travel ban, and then you punish countries like South Africa." He noted that South Africa should be praised for its transparency and not punished with restrictions, an act he thinks will lead to a chilling effect among other nations sharing data freely.
Blue Origin is gearing up for its next launch, set to blast off on December 9th. Michael Strahan is one of the six crew members who will snag a seat on the the New Shepard rocket. Jim Cantrell, CEO and co-founder at Phantom Space, joins Cheddar News to discuss.
Donald Pettey, Program Manager for Strategic Initiatives for MassDOT, and Mohammed Siddiqui, Vice President of Public Relations at Ko-Solar, join Cheddar Climate, where they discuss their plan to test highway barriers that absorb sound and solar energy, with construction expected to begin in the first half of 2022.
Over 100 world leaders signed on to a pledge at the United Nations COP26 climate meeting with the aim of ending and reversing deforestation by 2030. Leaders agreed to conserve forests and ecosystems, support developing countries on deforestation prevention, and more. Rod Taylor, Global Forests Director at the World Resources Institute, joins Cheddar Climate to discuss the pledge, whether it will have a significant impact, whether 2030 is a suitable deadline, and how we can verify if forests are actually being protected.
President Joe Biden's "Build Back Better" bill could mean cheaper electric bicycles and scooters as the nation attempts to shift away from gas-powered cars. Noa Banayan, the director of federal affairs at PeopleForBikes, joined Cheddar's "Closing Bell" to provide some background on the E-Bike Act included in Biden's reconciliation bill that would provide tax credits for qualified purchases. "We want to make sure, from the bike industry's perspective, that this is a technology and a product that is available to the majority of Americans who want to lower their carbon footprint and get around town faster and do everything that they would normally do in a short car trip but by bike, because it's healthier, it's fast, it's efficient, you're not in traffic," she said.
It's being called the next big trend in crypto. A decentralized autonomous organization, or DAO, is an internet community of different types of groups and businesses. The purpose is to allow people to commit funds to a specific cause in a safe way. Now, one social platform is creating a do-it-yourself kit for those who want to step into the space. Upstream Collective just launched the beta mode of its platform with the goal of putting all facets of running a DAO in one place. Alex Taub, co-founder and CEO of Upstream, joins Cheddar News to discuss.
A NASA spacecraft that will deliberately crash into an asteroid is preparing to launch this week. The goal of the DART mission, or the Double Asteroid Redirection Test, is to hit the smaller of the two asteroids, Dimorphos, with the spacecraft at about 15,000 miles per hour and see how the impact changes the asteroid’s trajectory. Joey Roulette, space reporter at The New York Times, joins Cheddar News to talk more about it.
NFL Hall of Famer and "Good Morning America" host Michael Strahan will be able to add space travel to his list of accomplishments as he prepares to launch into orbit with the next Blue Origin mission.
